Client Login Portal
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    Labaton Sucharow
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Contact Us
    • Knowledge Network
    • Client Login
    • Search
    • addthis
    • link : Client Login
    • knowledge network
    Labaton Sucharow
    • News & Events
      • Press Room
      • Published
      • Events
    • Digital Library
      • Videos
      • Podcasts
      • Webinars
    • News & Events
      • Press Room
      • Published
      • Events
      • The Liaison
    • Digital Library
      • Videos
      • Podcasts
      • Webinars

    The Biggest Competition Cases of 2017 So Far

    Law360
    July 7, 2017

    Gregory Asciolla remarks on the Actos decision in the wake of SCOTUS’ ruling in Actavis

    In an article touching on what Law360 is tracking to be some of the “biggest decisions in competition litigation” to date this year, partner Gregory Asciolla provided some commentary regarding the Actos antitrust litigation. The case, In re: Actos End-Payor Antitrust Litigation, alleged deception by diabetes drugmaker Takeda Pharmaceuticals Co., which produces Actos, to stifle generic competition for the drug.

    The drug purchasers originally alleged that settlement agreements Takeda made with the generics companies were unlawful reverse payments, but they later abandoned their pay-for-delay claims, leaving only state law antitrust claims. The Actos decision is one of a handful of recent circuit court rulings that have further clarified the intersection of antitrust and intellectual property law in the wake of the Supreme Court’s landmark ruling in 2013’s FTC v. Actavis.

    “The law is still developing after Actavis, and novel issues continue to be addressed by lower courts,” said Asciolla. The Actos decision will “help guide other courts on the law,” he said, “particularly on the pleading requirements relating to the causal connection between the conduct and the alleged delay in marketing a generic.”

    Useful Links

    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Center

    Our Locations

    footer-list-map_icon New York
    140 Broadway
    New York, NY 10005
    212-907-0700

    footer-list-map_icon Delaware
    222 Delaware Avenue, Suite 1510
    Wilmington, DE 19801
    302-573-2540

    Useful Links

    footer-list-map_icon Washington, D.C.
    1050 Connecticut Avenue, NW, Suite 500
    Washington, D.C. 20036
    212-907-0700

    Stay Connected

    • Facebook
    • Twitter
    • LinkedIn
    Labaton Sucharow
    • Attorney Advertising Disclaimer
    • Privacy Policy
    • Transparency in Coverage Rule
    • labaton.com
    • Labaton Sucharow All Rights Reserved 2023

    Attorney Advertising Disclaimer

    The materials appearing on this website are provided for informational purposes only and do not constitute legal advice. You should not take action based upon this information without consulting legal counsel. This site is not intended to create an attorney-client relationship. The hiring of a lawyer is an important decision that should not be based solely upon any single source of information, including advertising on this website. You may ask us to send you further information about us, and we urge you to review other sources of information about us.